Serina Therapeutics (NYSEAMERICAN:SER) Trading Down 1% – Should You Sell?

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) shares dropped 1% during mid-day trading on Friday . The stock traded as low as $1.98 and last traded at $2.07. Approximately 44,323 shares traded hands during trading, a decline of 4% from the average session volume of 46,056 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

Separately, BTIG Research started coverage on shares of Serina Therapeutics in a research report on Wednesday, July 1st. They set a “buy” rating and a $8.00 price target for the company. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $8.00.

Serina Therapeutics Stock Down 1.0%

The firm has a market cap of $31.05 million, a price-to-earnings ratio of -1.03 and a beta of 1.11. The company has a 50-day moving average of $1.93. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.18 and a quick ratio of 4.18.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its earnings results on Thursday, May 14th. The company reported ($0.58) EPS for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.